Loading
GC012F is an experimental CAR-T cell therapy from Gracell Biotechnologies (Shanghai) in phase 2 trials for multiple myeloma, aimed at CD19 and BCMA.
GC012F is a CAR-T cell therapy developed by Gracell Biotechnologies (Shanghai). Its targets are CD19 and BCMA (the sponsor names BCMA x CD19). The sponsor states: A dual chimeric antigen receptor (CAR) T-cell product engineered to recognise and attack multiple myeloma cells expressing either BCMA or CD19. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in multiple myeloma. The largest, NCT06235229, plans to enrol 110 participants with primary completion was scheduled for 2026-03-02 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.GC012F slips into a pocket on CD19.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"GC012F" OR ABSTRACT:"GC012F") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GC012F, not a curated reading list.
Shares BCMA, AstraZeneca, Multiple myeloma and the tag pipeline.
Shares BCMA, Multiple myeloma and the tag pipeline.
Shares AstraZeneca, Multiple myeloma and the tag pipeline.
Shares BCMA, Multiple myeloma and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares AstraZeneca and the tag pipeline.